Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2002 1
2011 1
2012 1
2015 1
2018 5
2019 5
2020 6
2021 9
2022 10
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Sharma P, et al. Among authors: pachynski rk. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10. Cancer Cell. 2020. PMID: 32916128 Free article. Clinical Trial.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK. Fizazi K, et al. Among authors: pachynski rk. J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761. J Immunother Cancer. 2022. PMID: 35977756 Free PMC article. Clinical Trial.
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK. Fizazi K, et al. Among authors: pachynski rk. Eur J Cancer. 2022 Jan;160:61-71. doi: 10.1016/j.ejca.2021.09.043. Epub 2021 Nov 18. Eur J Cancer. 2022. PMID: 34802864 Free article. Clinical Trial.
Treatment of Advanced Prostate Cancer.
Thomas TS, Pachynski RK. Thomas TS, et al. Among authors: pachynski rk. Mo Med. 2018 Mar-Apr;115(2):156-161. Mo Med. 2018. PMID: 30228709 Free PMC article. Review.
How else can we approach prostate cancer biomarker discovery?
Drake RR, Angel PM, Wu J, Pachynski RK, Ippolito JE. Drake RR, et al. Among authors: pachynski rk. Expert Rev Mol Diagn. 2020 Feb;20(2):123-125. doi: 10.1080/14737159.2019.1665507. Epub 2019 Sep 10. Expert Rev Mol Diagn. 2020. PMID: 31498690 Free PMC article. No abstract available.
Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D. Dehdashti F, et al. Among authors: pachynski rk. Mol Imaging Biol. 2022 Dec;24(6):853-861. doi: 10.1007/s11307-022-01746-w. Epub 2022 Jun 14. Mol Imaging Biol. 2022. PMID: 35701722 Free PMC article.
39 results